89bio announces positive topline results from its phase 1b/2a trial of BIO89-100 in NASH

89bio (Israel) announced on 14 September, 2020, positive topline results from its Phase 1b/2a trial with BIO89-100 in patients with NASH. BIO89-100 treatment group demonstrated significant reductions in liver fat.


For detailed information, see the below URL.


BIO89-100 is a FGF21 analog. Another FGF21 analog, Bristol-Myers Squibb's BMS-986036, is also currently undergoing Phase 2 trials.
We are looking forward to future clinical results.